References
- Goodman LS, Gilman A, Brunton LL, et al. Gilman’s: the pharmacological basis of therapeutics. McGraw-Hill. 2017;13:1440.
- France. Agence nationale de sécurité du médicamentet des produits de santé. Analyse desventes de medicaments en France en 2013. [National Agency for the Safety of Medicines and Health Products. Analysis of drugs sales in France in 2013. Paris 2014]; French. [cited 2017 Apr 05]. Available from: http://www.ansm.sante.fr/var/ansm_site/storage/original/application/3df7b99f8f4c9ee634a6a9b094624341.pdf
- Australia. The pharmaceutical benefits scheme (PBS) . expenditure and prescriptions twelve months to 30 June 2016. Canberra 2016 Dec 09. [ cited 2017 Jun 01]. Available from: http://www.pbs.gov.au/info/browse/statistics.
- International Marketing Statistics (IMS). The Global Use of Medicines: Outlook Through. Institute for Healthcare Informatics; 2012. [cited 2016 Oct 10]. Available from: https://www.imshealth.com/files/web/IMSH%20Institute/Reports/The%20Global%20Use%20of%20Medicines%20Outlook%20Through%202016/Medicines_Outlook_Through_2016_Report.pdf.
- Luz TCB, Osorio-de-Castro CGS, Magarinos-Torres R, et al. Trends in medicines procurement by the Brazilian Federal Government from 2006 to 2013. PloS One. 2017;12:e0174616.
- Brasil. Ministério da Saúde. Portaria nº 1554, de 30 de julho de 2013. Diário Oficial da União 2013. [Brazilian Ministry of Health. Ordinance number 1554, Jul 30, 2013. Brazilian National Gazette 2013]; Portuguese. [cited 2017 Mar 10]. Available from: http://portalarq10uivos.saude.gov.br/images/pdf/2014/abril/02/pt-gm-ms-1554-2013-alterada-1996-2013.pdf.
- Kwon HY, Yang B, Godman B. Key components of increased drug expenditure in South Korea: implications for the future. Value Health Reg Issues. 2015;6:14–21.
- Canada. Patented medicines prices review board. The Drivers of Prescription Drug Expenditures – A Methodological Report. National prescription drug utilization information system; 2016 Nov 05. [ cited 2017 Feb 01]. Available from: http://www.pmprb-cepmb.gc.ca/CMFiles/NPDUIS/NPDUIS_Drivers_Prescription_Drug_Expenditures_2013-12-13_EN.pdf
- Brasil. Casa Civil. Constituição da República Federativa do Brasil de 1988. Diário Oficial da União 05 Jan 2018. [Brazilian Civil House. Constitution of the Federative Republic of Brazil 1988. Brazilian National Gazette; 2018 Jan 05]; Portuguese. [ cited 2018 Jan 25]. Available from: http://www.planalto.gov.br/ccivil_03/constituicao/constituicao.htm.
- Brasil. Casa Civil. Lei n° 8.080, de 19 de setembro de 1990. Diário Oficial da União 20 Dez 2017. [Brazilian Civil House. Law number 8.080, Sep 19, 1990. Brazilian National Gazette 2017 Dec 20]. Portuguese. [ cited 2018 Jan 25]. Available from: http://www.planalto.gov.br/ccivil_03/leis/l8080.htm.
- Brasil. Ministério da Saúde. Portaria nº 2981, de 26 de Novembro de 2009. Diário Oficial da União 20 Jun 2016. [Brazilian Ministry of Health. Ordinance number 2981, Nov 26, 2009. Brazilian National Gazette 2016 Jun 20]; Portuguese. [ cited 2016 Jul 25]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt1554_30_07_2013.html.
- Gertham UG, Johannesson M, Gunnarsson B, et al. The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics. 1998;13:127–134.
- Addis A, Magrini N. New approaches to analyzing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. Pharmacoepidemiol Drug Saf. 2002;11:721–726.
- Canada. Canadian Institute for Health Information. Drivers of prescription drug spending in Canada. Ottawa 2012; [cited 2016 Jun 09]. Available from: https://secure.cihi.ca/free_products/Prescribed_Drug_Spending_in_Canada_EN.pdf.
- Brasil. Ministério da Saúde. Aquisição de Medicamentos para Assistência Farmacêutica no SUS. Brasília 25 Jan 2017. [Brazilian Ministry of Health. Acquisition of Medicines for Pharmaceutical Assistance in SUS. Brasilia 2017 Jan 25]; Portuguese. [ cited 2017 Mar 04]. Available from: http://www.ensp.fiocruz.br/portal-ensp/judicializacao/pdfs/284.pdf
- Willric MAV, Murray DL, Snyder R. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 2015;2:270–282.
- England. England Health and Social Care Information Centre. Prescribing Costs in Hospitals and the Community. London 2017 Jun 30. [ cited 2017 Jul 16]. Available from: http://www.digital.nhs.uk.
- Brasil. Agência Nacional de Vigilância Sanitária (ANVISA). Nota de esclarecimento nº 003/2017/GPBIO/GGMED/ANVISA, de 01 junho de 2017. [National Health Surveillance Agency (ANVISA). Note for clarification number 02-2012/GGMED/ANVISA, 2017 Jun 01]; Portuguese. [ cited 2017 Dec 29]. Available from: http://portal.anvisa.gov.br/documents/33840/324536/Nota+de+esclarecimento+N%C2%B0+003-2017-GPBIO-GGMED-ANVISA-+Intercambialidade+de+Biossimilares/c0ab22df-c2e7-4b28-a37d-2b80ffc18f33.
- Halpenny GM. High drug prices hurt everyone. ACS Med Chem Lett. 2016;6:544–546.
- Cuadrado MJ, Sciascia S, Bosch X, et al. Is it time for biosimilars in autoimmune diseases? Autoimmun Rev. 2013;12:954–957.
- Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PloS One. 2017;12:e0190147.
- Brasil. Ministério da Saúde. Resolução nº 55, de 16 de dezembro de 2010. Diário Oficial da União 20 Jun 2017. [Brazilian Ministry of Health. Resolution number 5516, Dec 16, 2010. Brazilian National Gazette 2017 Jun 20]. Portuguese. [ cited 2017 Jul 23]. Available from: http://portal.anvisa.gov.br/documents/33880/2568070/res0055_16_12_2010.pdf/7e0571b2-5d9b-4a92-b844-d9b665b185c4.
- Bangbola O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Ther Adv Endocrinol Metab. 2016;7:110–112.
- Brasil. Associação Brasileira de Transplante de Órgãos (ABTO). Dados numéricos da doação de órgãos e transplantes realizados por estado e instituição no período: janeiro/junho 2016. Brasília 17 Ago 2017. [Brazilian Association of Organ Transplants (ABTO). Numerical data on donation of organs and transplants performed by state and institution in the period: January/June 2016. Brasilia 2017 Aug 17]; Portuguese. [ cited 2017 Sep 14]. Available from: http://www.abto.org.br/abtov03/Upload/file/RBT/2016/1sem-RBT2016%20leitura.pdf.
- Almeida DEDS, Ceccato MDGB, Guerra Júnior AA, et al. Avaliação normativa do processo de prescrição e dispensação de imunossupressores para pacientes transplantados renais no estado de Minas Gerais, Brasil, 2008. [Normative evaluation of the process of prescribing and dispensing immunosuppressants for renal transplant patients in the state of Minas Gerais, Brazil, 2008]. Epidemiol Serv Saude. 2013;22:651–660.
- Gomes RM, Guerra Júnior AA, Lemos LLPD, et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Rev Clin Pharmacol. 2016;9:991–999.
- Rancic N, Vavic N, Obrencevic K, et al. Utilization and expenditure in Serbia. Front Public Health. 2017;5:291.
- Gardiner KM, Tett SE, Staatz CE. Multinational evaluation of mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and everolimus utilization. Ann Transplant. 2016;21:1–11.
- Lee EK, Cham TM, Tseng PL. A retrospective study on the utilization of and expenditure for immunosuppressants for organ transplant recipients in Taiwan–updated to 2006. Transplant Proc. 2010;3:961–965.
- De Souza ALC, de Assis Acurcio F, Guerra Júnior AA, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12:19–32.
- Prado MM. The debatable role of courts in Brazil’s health care system: does litigation harm or help? J Law Med Ethics. 2013;41:124–129.
- Biehl J, Amon JJ, Socal MP, et al. Between the court and the clinic: lawsuits for medicines and the right to health in Brazil. Health Hum Rights. 2012;14:36–52.
- Ferraz OLM. The right to health in the courts of Brazil: worsening health inequities? Health Hum Rights. 2009;1:33–45.
- Brasil. Ministério da Saúde. Medicamentos Biológicos (infliximabe, etanercepte, adalimumabe, rituximabe, abatacepte, tocilizumabe, golimumabe e certolizumabepegol) para o tratamento da Artrite Reumatóide. Brasília 2012. [Brazilian Ministry of Health. Biological Drugs (infliximab, etanercept, adalimumab, rituximab, abatacept, tocilizumab, golimumab and certolizumabepegol) for the treatment of rheumatoid arthritis. Brasilia 2012]; Portuguese. [cited 2017 Oct]. Available from: http://conitec.gov.br/images/Incorporados/Biologicos-ArtriteReumatoide-final.pdf.
- Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;1:1–15.
- USA. Food and Drug Administration (FDA); 2017. [cited 2017 Oct 07]. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm.
- Paumgartten FJ. Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness. Cad Saúde Pública. 2014;30:684–686.
- Zweegman S, van der Holt B, Mellqvist UH, et al. Levin MD and Gruber A. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016;9:1109–1116.
- Garrison LP, Wang ST, Huang H, et al. The cost-effectiveness of initial treatment of multiple myeloma in the US with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist. 2013;1:27–36.
- Brasil. Casa Civil. Lei n° 6360, de 23 de setembro de 1976. Diário Oficial da União 20 Jan 2018. [Brazilian Civil House. Law number 6360, Sep 23, 1976. Brazilian National Gazette 2018 Jan 20]; Portuguese. [ cited 2018 Jan 21]. Available from: http://portal.anvisa.gov.br/documents/33864/284972/lei_6360.pdf/5330c06d-1c17-4e1e-8d21-d7e3db4d3ce4
- Teodoro CRDS, Caetano R, Godman B, et al. Federal procurement of unlicensed medicines in Brazil; findings and implications. Rev Pharmacoecon Outcomes Res. 2017;1:1–7.
- Figueiredo TA. Schramm JMDA and Pepe VLE. Seleção de medicamentos essenciais e a carga de doença no Brasil. [Selection of essential drugs and disease burden in Brazil]. Cad Saúde Pública. 2014;30:2344–2356.
- Brasil. Ministério da Saúde. Judicialização da saúde no âmbito da união em números: Recursos Extraordinários. Brasília 15 Set 2017. [Brazilian Ministry of Health. Judicialization of health in the scope of union in numbers: Extraordinary Remedies. Brasilia 2017 Sep 15]; Portuguese. [ cited 2017 Oct 07]. Available from: http://portalarquivos.saude.gov.br/images/pdf/2017/maio/17/JUDICIALIZACAO%20DA%20SAUDE%20NO%20AMBITO%20DA%20UNIO%20EM%20NUMEROS%20Recursos%20Extraordinrios%20566471%20e%20657718.pdf.
- Martí-Carvajal AJ, Anand V, Cardona AF, et al. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. Cochrane Database Syst Rev. 2013;2:1-55.
- Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making. 2014;34:1016–1029.
- Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health Policy. 2014;116:137–146.
- Guerra Júnior AA, Pires de Lemos LL, Godman B, et al. Health technology performance assessment: real-world evidence for public healthcare sustainability. Int J Technol Assess Health Care. 2017;33:279–287.